Dismissal of the charges: The French Competition Authority finds no abuse where a drug company merely aligned its prices with competitors, despite possible source effects (Low molecular weight heparins)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. – Aut. conc. dec. no. 10-D-02 of 14 January 2010 on practices implemented in the low molecular weight heparin sector The Competition Authority concludes that a case relating to a possible anti-competitive leverage strategy has been dismissed. The case concerns sales at zero price of a preventive drug on the hospital market which should allow a strengthening of the market position of the same speciality in the city